Indications
Treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF) and adult patients with Progressive Pulmonary Fibrosis (PPF).
Composition
- Active substance
- nerandomilast
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jascayd
- Active substance
- nerandomilast
- Therapeutic area
- Idiopathic Pulmonary Fibrosis
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
- Status
- CHMP opinion
- EMA product number
- EMEA/H/C/006405
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No